In practice, American adults take GLP-1s for an average of 6 months
In phase III trials in patients with type 2 diabetes, once-weekly subcutaneous administration of semaglutide has been shown to significantly improve glycaemic control and reduce body weight compared with placebo when given as monotherapy, and compared with sitagliptin, extended-release exenatide or insulin glargine when given as add-on therapy to oral antidiabetic drugs [5,6,7,8]
Clinical trials of probiotic strains in selected disease entities
Early research suggests that compounded semaglutide might offer particular advantages for young women with PCOS, potentially providing an opportunity for early intervention in managing both metabolic and reproductive symptoms
If prescribed, it is essential to use Mounjaro in conjunction with healthy lifestyle changes, such as increased physical activity and a reduced-calorie diet
By effectively reducing visceral fat, the medication lowers systemic inflammation and insulin resistance, which are the precursors to most chronic diseases